Rhumbline Advisers Has $17.65 Million Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Rhumbline Advisers increased its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 15.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 597,331 shares of the company's stock after purchasing an additional 81,107 shares during the quarter. Rhumbline Advisers owned approximately 0.27% of Hims & Hers Health worth $17,651,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Blume Capital Management Inc. grew its holdings in shares of Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 600 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after buying an additional 1,413 shares during the last quarter. Summit Securities Group LLC acquired a new position in Hims & Hers Health during the 4th quarter worth about $38,000. US Bancorp DE grew its holdings in Hims & Hers Health by 346.7% during the 4th quarter. US Bancorp DE now owns 1,943 shares of the company's stock worth $47,000 after acquiring an additional 1,508 shares during the last quarter. Finally, Venturi Wealth Management LLC bought a new stake in Hims & Hers Health during the 4th quarter worth about $48,000. 63.52% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on HIMS shares. UBS Group reiterated a "mixed" rating on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Piper Sandler reaffirmed a "neutral" rating and set a $39.00 price objective (up previously from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Morgan Stanley decreased their price objective on Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating on the stock in a research report on Tuesday, April 29th. Needham & Company LLC boosted their target price on Hims & Hers Health from $61.00 to $65.00 and gave the stock a "buy" rating in a research report on Wednesday, June 4th. Finally, Canaccord Genuity Group raised their price target on Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $38.00.

Insider Buying and Selling

In other news, insider Irene Becklund sold 2,203 shares of the firm's stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $28.78, for a total transaction of $63,402.34. Following the sale, the insider now owns 8,007 shares of the company's stock, valued at $230,441.46. This trade represents a 21.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Melissa Baird sold 33,333 shares of the stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $25.78, for a total value of $859,324.74. Following the sale, the chief operating officer now directly owns 805,083 shares of the company's stock, valued at approximately $20,755,039.74. The trade was a 3.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 622,467 shares of company stock valued at $25,513,488. 13.71% of the stock is owned by company insiders.

Hims & Hers Health Trading Up 0.8%

Shares of HIMS stock traded up $0.47 on Monday, reaching $56.80. The company had a trading volume of 27,435,864 shares, compared to its average volume of 20,754,088. The company has a 50-day moving average of $42.23 and a 200-day moving average of $37.33. Hims & Hers Health, Inc. has a 12 month low of $13.47 and a 12 month high of $72.98. The stock has a market cap of $12.71 billion, a PE ratio of 129.09 and a beta of 2.09.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.12 by $0.08. The firm had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business's quarterly revenue was up 110.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.05 earnings per share. Sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.